![Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling](https://www.science.org/cms/10.1126/scisignal.aai8441/asset/fd6b7b37-c5b5-4cc4-a506-60837b2b56c2/assets/graphic/9_ra117_f4.jpeg)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
![Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling](https://www.science.org/cms/10.1126/scisignal.aai8441/asset/c4b5daf9-bb92-4d81-a968-9dba715fc066/assets/graphic/9_ra117_f3.jpeg)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
![The Role of Mu-Opioids for Reward and Threat Processing in Humans: Bridging the Gap from Preclinical to Clinical Opioid Drug Studies | SpringerLink The Role of Mu-Opioids for Reward and Threat Processing in Humans: Bridging the Gap from Preclinical to Clinical Opioid Drug Studies | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40429-021-00366-8/MediaObjects/40429_2021_366_Fig1_HTML.png)
The Role of Mu-Opioids for Reward and Threat Processing in Humans: Bridging the Gap from Preclinical to Clinical Opioid Drug Studies | SpringerLink
![The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain | Neuropsychopharmacology The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain | Neuropsychopharmacology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnpp.2017.204/MediaObjects/41386_2018_Article_BFnpp2017204_Fig1_HTML.jpg)
The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain | Neuropsychopharmacology
![A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0223523422006870-gr1.jpg)
A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect
![Human brain opioid receptor PET images in coronal (upper row) and axial... | Download Scientific Diagram Human brain opioid receptor PET images in coronal (upper row) and axial... | Download Scientific Diagram](https://www.researchgate.net/publication/337338731/figure/fig1/AS:826866776678406@1574151810192/Human-brain-opioid-receptor-PET-images-in-coronal-upper-row-and-axial-lower-row.png)
Human brain opioid receptor PET images in coronal (upper row) and axial... | Download Scientific Diagram
![Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling](https://www.science.org/cms/10.1126/scisignal.aai8441/asset/46ae1e57-be51-4561-8c82-fec4afe7f398/assets/graphic/9_ra117_f5.jpeg)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
![IJMS | Free Full-Text | A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases IJMS | Free Full-Text | A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases](https://pub.mdpi-res.com/ijms/ijms-21-00065/article_deploy/html/images/ijms-21-00065-g001.png?1579160575)
IJMS | Free Full-Text | A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases
![Opioid system and human emotions - Nummenmaa - 2018 - British Journal of Pharmacology - Wiley Online Library Opioid system and human emotions - Nummenmaa - 2018 - British Journal of Pharmacology - Wiley Online Library](https://bpspubs.onlinelibrary.wiley.com/cms/asset/53970599-d0db-49ac-8df6-253f74e6eed2/bph13812-fig-0001-m.jpg)
Opioid system and human emotions - Nummenmaa - 2018 - British Journal of Pharmacology - Wiley Online Library
![Mixed Kappa/Mu Partial Opioid Agonists as Potential Treatments for Cocaine Dependence - ScienceDirect Mixed Kappa/Mu Partial Opioid Agonists as Potential Treatments for Cocaine Dependence - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-B978012420118700010X-f10-01-9780124201187.jpg)
Mixed Kappa/Mu Partial Opioid Agonists as Potential Treatments for Cocaine Dependence - ScienceDirect
![A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0223523422006870-gr5.jpg)
A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect
![A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0223523422006870-gr2.jpg)
A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect
![A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0223523422006870-gr3.jpg)
A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect
![A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0223523422006870-gr6.jpg)
A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect
![Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling](https://www.science.org/cms/10.1126/scisignal.aai8441/asset/ff263f7b-fb91-41c8-a085-c49363544450/assets/graphic/9_ra117_f6.jpeg)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
![Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA) Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)](http://nida.nih.gov/sites/default/files/images/valenza_zamarripa_fig1.gif)
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
![Subtlety of the Structure−Affinity and Structure−Efficacy Relationships around a Nonpeptide Oxytocin Receptor Agonist | Journal of Medicinal Chemistry Subtlety of the Structure−Affinity and Structure−Efficacy Relationships around a Nonpeptide Oxytocin Receptor Agonist | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/jm901084f/asset/images/medium/jm-2009-01084f_0011.gif)
Subtlety of the Structure−Affinity and Structure−Efficacy Relationships around a Nonpeptide Oxytocin Receptor Agonist | Journal of Medicinal Chemistry
![Opioid antagonism in humans: a primer on optimal dose and timing for central mu-opioid receptor blockade | Neuropsychopharmacology Opioid antagonism in humans: a primer on optimal dose and timing for central mu-opioid receptor blockade | Neuropsychopharmacology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41386-022-01416-z/MediaObjects/41386_2022_1416_Fig1_HTML.png)
Opioid antagonism in humans: a primer on optimal dose and timing for central mu-opioid receptor blockade | Neuropsychopharmacology
The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence
![A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0223523422006870-ga1.jpg)
A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect
![The RGSZ2 Protein Exists in a Complex with μ-Opioid Receptors and Regulates the Desensitizing Capacity of Gz Proteins | Neuropsychopharmacology The RGSZ2 Protein Exists in a Complex with μ-Opioid Receptors and Regulates the Desensitizing Capacity of Gz Proteins | Neuropsychopharmacology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fsj.npp.1300726/MediaObjects/41386_2005_Article_BF1300726_Fig1_HTML.jpg)